Amicus Therapeutics, Inc. provided earnings guidance for the year 2023. For the full-year 2023, the company anticipates total Galafold revenue growth between 12% and 17% at CER driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.2 USD | -4.13% | +1.29% | -28.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.26% | 3.15B | |
+40.01% | 55.66B | |
-8.20% | 38.98B | |
+35.79% | 38.8B | |
-8.98% | 27.32B | |
+10.61% | 26.29B | |
-16.25% | 20.25B | |
+30.72% | 12.76B | |
+28.34% | 12.18B | |
-1.14% | 12.12B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023